Junevity Raises $20M to Advance First-in-Class siRNA Cell Reprogramming Therapy for Metabolic Disorders
核心洞察
Junevity (搜索) doubled its seed funding to $20 million to advance JUN_01 (搜索), a novel siRNA therapy that reprograms metabolic tissues to healthier states for treating type 2 diabetes (搜索) and obesity (搜索).
The lead candidate JUN_01 (搜索) demonstrated improved insulin sensitivity, weight loss, and lean mass preservation in preclinical studies with dosing required only every six months.
First-in-human trials are expected to begin in the second half of 2026, marking the first clinical application of siRNA-based cell reprogramming for metabolic dysfunction.
Biotechnology company Junevity (搜索) announced on December 3, 2025, that it has expanded its seed funding to $20 million with a newly added $10 million investment led by Goldcrest Capital (搜索) and Godfrey Capital (搜索). The San Francisco-based company plans to use the capital to advance its lead candidate, JUN_01 (搜索), toward investigational new drug-enabling work and initial clinical studies for type 2 diabetes (搜索) and obesity (搜索).
Novel siRNA Platform Targets Transcription Factors
Junevity (搜索)'s approach represents a departure from traditional metabolic interventions by using small interfering RNA (siRNA) to reprogram cells to healthier states. The company's scientific founders were the first to demonstrate that repressing a single transcription factor could revert human cells to a healthier state, establishing the foundation for the company's technology platform.
The therapeutic concept focuses on identifying and suppressing transcription factors (搜索) that drive chronic metabolic dysfunction. JUN_01 (搜索) targets a regulator implicated in insulin signaling (搜索) and appetite, selected through Junevity (搜索)'s discovery platform called RESET, which integrates human disease data, genetic linkages, and computational analyses.
"JUN_01 (搜索) is a next-generation siRNA candidate for type 2 diabetes (搜索) and obesity (搜索) and the first cell reprogramming candidate with siRNA for metabolism," said John Hoekman, co-founder and CEO of Junevity (搜索). "By reprogramming metabolic tissue to a healthy state, we see profound and durable benefits beyond today's standard of care."
Promising Preclinical Results
Preclinical data suggest that JUN_01 (搜索) acts by reprogramming metabolic tissues to a healthier state. Studies showed reduced blood glucose, improved insulin sensitivity, weight loss, and lean-mass preservation, alongside infrequent dosing and safety attributes associated with siRNA modalities. In preclinical models, JUN_01 reprogrammed metabolic tissues toward profiles resembling those of younger, healthier animals, driving significant fat-selective weight loss while preserving lean mass.
A notable finding from early studies indicates potential resistance to weight regain once treatment stops—addressing a persistent challenge with current metabolic interventions. The therapy requires dosing only every six months, which could significantly improve patient adherence compared to existing treatments.
"JUN_01 (搜索) offers a unique and promising combination of improved insulin sensitivity and weight loss, with dosing every six months," said John Bamforth, PhD, former chief marketing officer at Eli Lilly and Company and advisor to Junevity (搜索). "This profile could fill an important need for effective and tolerable long-term diabetes and weight management either alone or in combination with GLP-1s."
Clinical Timeline and Broader Applications
First-in-human trials are anticipated to start in the second half of 2026, marking what would be the first clinical application of siRNA-based cell reprogramming for metabolic dysfunction. If successful, this approach may introduce a new direction for metabolic therapies and influence how combination regimens with incretin-based drugs are structured.
The company's platform stems from research conducted at the University of California, San Francisco, where co-founder Janine Sengstack developed methods to use omics, genetic data, and machine-learning tools to identify new transcription factor targets. These targets have traditionally been difficult to drug, and the ability to reach them with siRNA could widen the landscape of therapeutic discovery.
Beyond metabolism, Junevity (搜索) is expanding research into neurodegeneration (搜索) and other areas involving complex tissue dysfunction. The company has expressed interest in muscle wasting conditions such as cachexia (搜索) and sarcopenia (搜索), as well as osteoarthritis (搜索), building on its framework for systematically restoring cellular homeostasis across organs affected by complex disease.
The broader significance of this research lies in whether siRNA-driven transcription factor modulation can become a translatable therapeutic model for conditions historically limited by target accessibility, potentially opening new avenues for treating age-related diseases through cellular reprogramming.